Sun turns down Guggenheim's offer for its Taro shares
This article was originally published in Scrip
Executive Summary
India's Sun Pharmaceutical Industries appears determined to stand firm in its quest to take control of Taro Pharmaceutical Industries. Sun has rejected an offer from the New York-based investment banking firm, Guggenheim Securities, to buy its stake in Taro at $15 per share on behalf of a group of institutional investors.